-
市場
-
產品
-
資訊
-
Moo社區
-
課堂
-
查看更多
-
功能介紹
-
費用費用透明,無最低余額限制
投資選擇、功能介紹、費用相關信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 淺色
Head-To-Head Review: Cardio Diagnostics (NASDAQ:CDIO) Versus Celldex Therapeutics (NASDAQ:CLDX)
Head-To-Head Review: Cardio Diagnostics (NASDAQ:CDIO) Versus Celldex Therapeutics (NASDAQ:CLDX)
Cardio Diagnostics (NASDAQ:CDIO – Get Rating) and Celldex Therapeutics (NASDAQ:CLDX – Get Rating) are both medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their dividends, valuation, analyst recommendations, risk, institutional ownership, profitability and earnings.
Valuation and Earnings
This table compares Cardio Diagnostics and Celldex Therapeutics' top-line revenue, earnings per share (EPS) and valuation.
Get Cardio Diagnostics alerts:Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
Cardio Diagnostics | N/A | N/A | -$140,000.00 | N/A | N/A |
Celldex Therapeutics | $4.65 million | 468.47 | -$70.51 million | ($2.26) | -20.46 |
Cardio Diagnostics has higher earnings, but lower revenue than Celldex Therapeutics.
Analyst Recommendations
This is a breakdown of current recommendations and price targets for Cardio Diagnostics and Celldex Therapeutics, as provided by MarketBeat.Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
Cardio Diagnostics | 0 | 0 | 0 | 0 | N/A |
Celldex Therapeutics | 0 | 0 | 4 | 0 | 3.00 |
Cardio Diagnostics presently has a consensus target price of $8.00, suggesting a potential upside of 669.23%. Celldex Therapeutics has a consensus target price of $66.67, suggesting a potential upside of 44.14%. Given Cardio Diagnostics' higher possible upside, analysts plainly believe Cardio Diagnostics is more favorable than Celldex Therapeutics.
Profitability
This table compares Cardio Diagnostics and Celldex Therapeutics' net margins, return on equity and return on assets.
Net Margins | Return on Equity | Return on Assets | |
Cardio Diagnostics | N/A | N/A | N/A |
Celldex Therapeutics | -9,840.85% | -25.47% | -23.72% |
Insider and Institutional Ownership
77.3% of Cardio Diagnostics shares are owned by institutional investors. 2.7% of Celldex Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.
Summary
Cardio Diagnostics beats Celldex Therapeutics on 6 of the 9 factors compared between the two stocks.
About Cardio Diagnostics
(Get Rating)
Cardio Diagnostics Holdings, Inc., a biotechnology company, develops and commercializes epigenetics-based clinical tests for cardiovascular disease. It offers Epi+Gen, a three-year symptomatic coronary heart disease (CHD) risk assessment test targeting CHD events, including heart attacks. The company was founded in 2017 and is headquartered in Chicago, Illinois.
About Celldex Therapeutics
(Get Rating)
Celldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory diseases and various forms of cancer. The company's clinical development programs CDX-0159, a Phase I monoclonal antibody that binds the receptor tyrosine kinase KIT and inhibits its activity; CDX-1140, a human agonist monoclonal antibody targeted to CD40, a key activator of immune response, which is found on dendritic cells, macrophages, and B cells, as well as is expressed on various cancer cells; and CDX-527, a bispecific antibody, which uses the company's proprietary active anti-PD-L1 and CD27 human antibodies to couple CD27 costimulation with blockade of the PD-L1/PD-1 pathway to help prime and activate anti-tumor T cell responses through CD27 costimulation. The company has research collaboration and license agreements with University of Southampton to develop human antibodies towards CD27; Amgen Inc. with exclusive rights to CDX-301 and CD40 ligand; and Yale University. Celldex Therapeutics, Inc. was incorporated in 1983 and is headquartered in Hampton, New Jersey.
Receive News & Ratings for Cardio Diagnostics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cardio Diagnostics and related companies with MarketBeat.com's FREE daily email newsletter.
Cardio Diagnostics (NASDAQ:CDIO – Get Rating) and Celldex Therapeutics (NASDAQ:CLDX – Get Rating) are both medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their dividends, valuation, analyst recommendations, risk, institutional ownership, profitability and earnings.
心臟診斷公司(納斯達克:CDIO-GET評級)和細胞治療公司(納斯達克:CLDX-GET評級)都是醫療公司,但哪一項投資更具優勢?我們將根據這兩家公司的股息實力、估值、分析師建議、風險、機構所有權、盈利能力和收益對它們進行比較。
Valuation and Earnings
估值和收益
This table compares Cardio Diagnostics and Celldex Therapeutics' top-line revenue, earnings per share (EPS) and valuation.
此表比較了Cardio Diagnostics和Celldex Treeutics的營收、每股收益(EPS)和估值。
Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
Cardio Diagnostics | N/A | N/A | -$140,000.00 | N/A | N/A |
Celldex Therapeutics | $4.65 million | 468.47 | -$70.51 million | ($2.26) | -20.46 |
總收入 | 價格/銷售額比 | 淨收入 | 每股收益 | 市盈率 | |
心臟診斷學 | 不適用 | 不適用 | -$140,000.00 | 不適用 | 不適用 |
Celldex治療公司 | 465萬美元 | 468.47 | -7051萬美元 | ($2.26) | -20.46 |
Cardio Diagnostics has higher earnings, but lower revenue than Celldex Therapeutics.
心臟診斷公司的收益比Celldex Treeutics高,但收入較低。
Analyst Recommendations
分析師建議
Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
Cardio Diagnostics | 0 | 0 | 0 | 0 | N/A |
Celldex Therapeutics | 0 | 0 | 4 | 0 | 3.00 |
銷售評級 | 保持評級 | 購買評級 | 強勁的買入評級 | 評級分數 | |
心臟診斷學 | 0 | 0 | 0 | 0 | 不適用 |
Celldex治療公司 | 0 | 0 | 4 | 0 | 3.00 |
Cardio Diagnostics presently has a consensus target price of $8.00, suggesting a potential upside of 669.23%. Celldex Therapeutics has a consensus target price of $66.67, suggesting a potential upside of 44.14%. Given Cardio Diagnostics' higher possible upside, analysts plainly believe Cardio Diagnostics is more favorable than Celldex Therapeutics.
心臟診斷公司目前的共識目標價為8.00美元,暗示潛在上漲669.23%。Celldex Treateutics的共識目標價為66.67美元,暗示潛在上漲44.14%。考慮到Cardio診斷公司更有可能的上行空間,分析師們顯然認為Cardio診斷公司比Celldex治療公司更有利。
Profitability
盈利能力
This table compares Cardio Diagnostics and Celldex Therapeutics' net margins, return on equity and return on assets.
此表比較了Cardio Diagnostics和Celldex Treeutics的淨利潤率、股本回報率和資產回報率。
Net Margins | Return on Equity | Return on Assets | |
Cardio Diagnostics | N/A | N/A | N/A |
Celldex Therapeutics | -9,840.85% | -25.47% | -23.72% |
淨利潤率 | 股本回報率 | 資產回報率 | |
心臟診斷學 | 不適用 | 不適用 | 不適用 |
Celldex治療公司 | -9,840.85% | -25.47% | -23.72% |
Insider and Institutional Ownership
內部人與機構持股
77.3% of Cardio Diagnostics shares are owned by institutional investors. 2.7% of Celldex Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.
Cardio Diagnostics 77.3%的股份由機構投資者持有。Celldex治療公司2.7%的股份由內部人士持有。強大的機構持股表明,大型基金管理公司、對衝基金和捐贈基金相信,一家公司的長期表現將好於大盤。
Summary
摘要
Cardio Diagnostics beats Celldex Therapeutics on 6 of the 9 factors compared between the two stocks.
在兩隻股票之間的9個因素中,心臟診斷公司在6個因素上擊敗了Celldex治療公司。
About Cardio Diagnostics
關於Cardio診斷公司
(Get Rating)
(獲取評級)
Cardio Diagnostics Holdings, Inc., a biotechnology company, develops and commercializes epigenetics-based clinical tests for cardiovascular disease. It offers Epi+Gen, a three-year symptomatic coronary heart disease (CHD) risk assessment test targeting CHD events, including heart attacks. The company was founded in 2017 and is headquartered in Chicago, Illinois.
心臟診斷控股公司是一家生物技術公司,開發和商業化基於表觀遺傳學的心血管疾病臨牀測試。它提供Epi+Gen,這是一種為期三年的症狀性冠心病(CHD)風險評估測試,針對包括心臟病發作在內的CHD事件。該公司成立於2017年,總部位於伊利諾伊州芝加哥。
About Celldex Therapeutics
關於Celldex治療公司
(Get Rating)
(獲取評級)
Celldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory diseases and various forms of cancer. The company's clinical development programs CDX-0159, a Phase I monoclonal antibody that binds the receptor tyrosine kinase KIT and inhibits its activity; CDX-1140, a human agonist monoclonal antibody targeted to CD40, a key activator of immune response, which is found on dendritic cells, macrophages, and B cells, as well as is expressed on various cancer cells; and CDX-527, a bispecific antibody, which uses the company's proprietary active anti-PD-L1 and CD27 human antibodies to couple CD27 costimulation with blockade of the PD-L1/PD-1 pathway to help prime and activate anti-tumor T cell responses through CD27 costimulation. The company has research collaboration and license agreements with University of Southampton to develop human antibodies towards CD27; Amgen Inc. with exclusive rights to CDX-301 and CD40 ligand; and Yale University. Celldex Therapeutics, Inc. was incorporated in 1983 and is headquartered in Hampton, New Jersey.
生物製藥公司Celldex Treateutics,Inc.致力於開發治療各種疾病的治療性單抗和雙特異性抗體。它的候選藥物包括治療炎症性疾病和各種形式癌症的抗體療法。該公司的臨牀開發計劃包括CDX-0159,這是一種I期單抗,可以結合受體酪氨酸激酶試劑盒並抑制其活性;CDX-1140是一種針對CD40的人類激動型單抗,CD40是免疫反應的關鍵激活劑,存在於樹突狀細胞、巨噬細胞和B細胞上,也表達在各種癌細胞上;以及CDX-527,它是一種雙特異性抗體,使用公司專有的活性抗PD-L1和CD27人類抗體來偶聯CD27共刺激,阻斷PD-L1/PD-1途徑,通過CD27共刺激幫助啟動和激活抗腫瘤T細胞反應。該公司與南安普頓大學、擁有CDX-301和CD40配體獨家經營權的安進公司以及耶魯大學簽訂了研究合作和許可協議,以開發針對CD27的人類抗體。Celldex治療公司成立於1983年,總部設在新澤西州的漢普頓。
Receive News & Ratings for Cardio Diagnostics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cardio Diagnostics and related companies with MarketBeat.com's FREE daily email newsletter.
接收《心臟診斷日報》的新聞和評級-在下面輸入您的電子郵件地址,通過MarketBeat.com的免費每日電子郵件時事通訊接收對Cardio Diagnostics和相關公司的最新新聞和分析師評級的每日摘要。
moomoo是Moomoo Technologies Inc.公司提供的金融資訊和交易應用程式。
在美國,moomoo上的投資產品和服務由Moomoo Financial Inc.提供,一家受美國證券交易委員會(SEC)監管的持牌主體。 Moomoo Financial Inc.是金融業監管局(FINRA)和證券投資者保護公司(SIPC)的成員。
在新加坡,moomoo上的投資產品和服務是通過Moomoo Financial Singapore Pte. Ltd.提供,該公司受新加坡金融管理局(MAS)監管(牌照號碼︰CMS101000) ,持有資本市場服務牌照 (CMS) ,持有財務顧問豁免(Exempt Financial Adviser)資質。本內容未經新加坡金融管理局的審查。
在澳大利亞,moomoo上的金融產品和服務是通過Futu Securities (Australia) Ltd提供,該公司是受澳大利亞證券和投資委員會(ASIC)監管的澳大利亞金融服務許可機構(AFSL No. 224663)。請閱讀並理解我們的《金融服務指南》、《條款與條件》、《隱私政策》和其他披露文件,這些文件可在我們的網站 https://www.moomoo.com/au中獲取。
在加拿大,透過moomoo應用程式提供的僅限訂單執行的券商服務由Moomoo Financial Canada Inc.提供,並受加拿大投資監管機構(CIRO)監管。
在馬來西亞,moomoo上的投資產品和服務是透過Moomoo Securities Malaysia Sdn. Bhd. 提供,該公司受馬來西亞證券監督委員會(SC)監管(牌照號碼︰eCMSL/A0397/2024) ,持有資本市場服務牌照 (CMSL) 。本內容未經馬來西亞證券監督委員會的審查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd.,Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc和Moomoo Securities Malaysia Sdn. Bhd., 是關聯公司。
風險及免責聲明
moomoo是Moomoo Technologies Inc.公司提供的金融資訊和交易應用程式。
在美國,moomoo上的投資產品和服務由Moomoo Financial Inc.提供,一家受美國證券交易委員會(SEC)監管的持牌主體。 Moomoo Financial Inc.是金融業監管局(FINRA)和證券投資者保護公司(SIPC)的成員。
在新加坡,moomoo上的投資產品和服務是通過Moomoo Financial Singapore Pte. Ltd.提供,該公司受新加坡金融管理局(MAS)監管(牌照號碼︰CMS101000) ,持有資本市場服務牌照 (CMS) ,持有財務顧問豁免(Exempt Financial Adviser)資質。本內容未經新加坡金融管理局的審查。
在澳大利亞,moomoo上的金融產品和服務是通過Futu Securities (Australia) Ltd提供,該公司是受澳大利亞證券和投資委員會(ASIC)監管的澳大利亞金融服務許可機構(AFSL No. 224663)。請閱讀並理解我們的《金融服務指南》、《條款與條件》、《隱私政策》和其他披露文件,這些文件可在我們的網站 https://www.moomoo.com/au中獲取。
在加拿大,透過moomoo應用程式提供的僅限訂單執行的券商服務由Moomoo Financial Canada Inc.提供,並受加拿大投資監管機構(CIRO)監管。
在馬來西亞,moomoo上的投資產品和服務是透過Moomoo Securities Malaysia Sdn. Bhd. 提供,該公司受馬來西亞證券監督委員會(SC)監管(牌照號碼︰eCMSL/A0397/2024) ,持有資本市場服務牌照 (CMSL) 。本內容未經馬來西亞證券監督委員會的審查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd.,Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc和Moomoo Securities Malaysia Sdn. Bhd., 是關聯公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用瀏覽器的分享功能,分享給你的好友吧